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ABSTRACT  Bovine  brain,  hypothalamus,  pituitary,  and  retina  contain  potent  anionic  polypeptide 
mitogens  for endothelial  cells.  Immunological  assays using  murine  monoclonal  antibodies  against 
bovine  endothelial  cell growth factor  (ECGF) and  radioreceptor assays using  [1251]ECGF were per- 
formed  to  determine  the  cross-reactivity  of  ECGF with  bovine  acidic  pl  brain-derived  fibroblast 
growth  factor  (acidic  FGF) and  bovine  eye-derived  growth factor-II  (EDGF-II).  We  observed  that 
acidic FGF and EDGF-II are recognized by anti-ECGF monoclonal antibodies and compete with [1251] 
ECGF for receptor occupancy.  Furthermore, the biological activity of ECGF, acidic FGF, and EDGF- 
II is potentiated by the glycosylaminoglycan,  heparin. These results argue that ECGF, acidic FGF, and 
EDGF-II belong to a common family of polypeptide growth factors. 
Several growth factors of peptidic nature have been isolated 
and purified from bovine neural tissue (1, 4-6, 9,  10, 14-19, 
23,  24). These polypeptides share common biological  prop- 
erties since they are all potent mitogens for murine BALB/c 
3T3 cells in vitro. In addition, several  of these polypeptide 
mitogens stimulate endothelial cell proliferation in vitro (1, 
5, 6,  11,  13,  16,  18,  19, 23, 24) and may play an important 
role in homeostatic and pathophysiological processes involv- 
ing the vascular tree (21). These growth factors include poly- 
peptides of cationic nature such as basic isoelectric point (pI) ~ 
fibroblast growth factor (FGF) (4,  10), chondrosarcoma-de- 
1  Abbreviations  used in this paper."  BAEC, bovine aortic endothelial 
cells; DME-BSA,  Dulbecco's modified  Eagle's  medium,  pH  7.4, 
containing 0.1% bovine serum albumin and 50 mM HEPES; ECGF, 
endothelial  cell growth factor; EDGF-II, eye-derived growth factor; 
EGF, epidermal growth factor; FGF, fibroblast growth factor; HDGF, 
hypothalamus-derived growth factor; HUVEC, human umbilical vein 
endothelial  cell; HGF, heparin-binding  growth factor; pI, isoelectric 
point; RDGF, retina-derived growth factor. 
rived growth factor (23), and basic pI hypothalamus-derived 
growth factor-I (HDGF), as well as polypeptide mitogens with 
anionic isoelectric points. These acidic growth factors include 
endothelial cell growth factor (ECGF) (18, 19), acidic pI brain- 
derived FGF (9, 24), eye-derived growth factor-II (EDGF-II) 
(1-3),  retina-derived growth factor (RDGF) (6), a-heparin- 
binding growth factor (a-HGF) (18), and acidic pI HDGF 
(15). Radioreceptor and immunological assays have recently 
been developed for the acidic polypeptide, ECGF (20,  22). 
The availability of purified growth factors and these charac- 
terization methods prompted us to determine whether these 
endothelial cell mitogens share common immunological and 
cell receptor recognition features.  We now report that both 
acidic FGF and EDGF-II compete with ECGF for receptor 
occupancy and cross-react  with monoclonal antibodies pre- 
pared against ECGF. Furthermore, the mitogenic activity of 
the acidic polypeptide growth factors acidic FGF and EDGF- 
II on endothelial cells is potentiated by the glycosaminogly- 
can, heparin, a biological attribute unique to ECGF (22). 
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Reagents:  Epidermal  growth  factor (EGF)  was  purified  from  male 
mouse submaxillary  glands by reverse-phase high pressure liquid chromatog- 
raphy as previously described (22). Basic FGF, purified to homogeneity from 
bovine pituitary glands (4) was a generous gift from Dr. Denis Gospodarowicz 
and ECGF (M, -  20,000) and acidic FGF (M, =-  17,000) was purified  from 
bovine brain by procedures previously described (20, 24) (Burgess, W. H., T. 
Mehlman, R. Friesel, W. Johnson and T.  Maciag, J. Biol. Chem., In press). 
Purified preparations of EDGF-II were obtained from bovine retina by extrac- 
lion and Afti-Blue chromatography as described  (3), followed by elution of 
EDGF-II from heparin-Sepharose  between 0.9 and I. l  M NaCl (20). Murine 
monoclonal antibodies and  rabbit polyclonal  antisera against  ECGF were 
prepared as previously described (20, 22). The monocional antibodies H9, an 
IgM(k), and H 15 an IgG2(k) are neutralizing antibodies for ECGF (22). Heparin 
and bovine serum albumin (BSA) were obtained from Armour Pharmaceutical 
Co. (Tarrytown, NY) and heparin-Sepharose  6B was purchased from Pharmacia 
Fine Chemicals (Piseataway, N J). 
Cells:  Human  umbilical  vein endothelial cells (HUVEC) and bovine 
aortic endothelial cells (BAEC) were established  from primary cultures.  HU- 
VEC were grown on human fibroncetin--coated  (5 #g/cm  2) (Armour Pharma- 
ceutical Co.) cell culture dishes in Dulbecco's modified Eagle's medium (DME) 
containing 10% fetal bovine serum (HyClone Laboratories,  Logan, UT) and 2 
ng/ml ECGF containing 20 tzg heparin/ml. BAEC were propagated in DMEM 
containing 10% fetal bovine serum. The endothelial cell character of  the BAEC 
and HUVEC populations was confirmed by the presence of human Factor 
VIII:Ag and membrane anglotensin-converting  enzyme (monoclonal antibody 
against angiotensin-converting enzyme kindly provided by Dr.  R. Auerbach) 
as previously described (20). 
Cell Proliferation Assay:  The low seed density human endothelial 
cell proliferation  assay was performed with HUVEC as previously described 
(2 l, 25). Briefly, HUVEC were seeded ( lO  a cells/cm  2) on human fibronectin (5 
ug/cm  2) in 96-well cluster dishes (Costar,  Cambridge,  MA) in DME supple- 
mented with 10% FBS. Mitogens were added for 3 d at 37"C prior to protein 
determination as described in Results. The incorporation of [aH]methylthymi- 
dine (New England Nuclear,  Boston, MA) into DNA in quiescent BAEC was 
performed as previously described for routine lung capillary endothelial  cells 
(20, 25). 
Radioreceptor Binding Assay:  The ligand, ECGF, was radiolabeled 
with Na=25I using Enzymobeads (immobilized glucose-oxidaselactoperoxidase, 
Bio-Rad Laboratories, Richmond, CA) as previously described (22). The radio- 
labeled  ligand,  [mI]ECGF, possessed a  specific activity  of 2  x  l04 cpm/ng 
protein and was biologically active at 500  pg/ml. Confluent populations of 
BAEC in 24-well cluster dishes (Costar) were washed twice with DME, pH 7.4, 
containing 0.1% BSA and 50 mM HEPES (DME-BSA). The cells were incu- 
bated at 4*(2 for 60 min with [t251]ECGF in the presence or absence of  inhibitor 
polypeptides in DME-BSA, washed three times with DME-BSA, lysed with 
0. l N NaOH, and the cell-associated radioactivity was determined. Nonspecific 
binding was assessed in the presence of 100-fold molar excess of cold ECGF 
and did not exceed 20% of the total binding. 
Double-Antibody Immunoassay:  The  immunoassay was  per- 
formed as previously described (22). Briefly, polyvinylchloride  96-well plates 
(Costar) were coated with 50 tag/ml polyclonal rabbit anti-ECGF (lgG), coun- 
tercoated with 10% normal rabbit serum, incubated with increasing concentra- 
tions of polypeptide ligand,  washed with  DME-BSA, and  incubated with 
monoclonai anti-ECGF antibodies (20,  22).  The  reaction was quantitated 
spectrophotometrically  after incubation with peroxidase-conjugated rabbit anti- 
mouse IgG or lgM (Zymed Laboratories,  San Francisco, CA) and orthophen- 
ylenediamine substrate conversion. 
RESULTS 
Acidic FGF and EDGF-II Compete for [~2St]ECGF 
Binding to Endothelial Cell Receptors 
As reported previously,  [125I]ECGF binds to HUVEC  and 
BAEC in a reversible and saturable fashion (22). The apparent 
Ko for receptor occupancy  was estimated to be, respectively, 
2  and 6  x  l0  -~° M  with 4  and 2  x  l04 binding sites per cell 
(22).  Both  acidic  FGF  and  EDGF-II,  but  neither  EGF  nor 
cationic FGF, compete for the specific binding of [~2SI]ECGF 
to both cell types in a  concentration-dependent  manner.  The 
experimental  results obtained with  BAEC  are shown  in Fig. 
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1. The polypeptides ECGF, EDGF-II, and acidic FGF com- 
pete half-maximally at ~10 -9 M. Molarities were calculated 
for acidic FGF (Mr 17,000), EDGF-II (Mr 17,000), and ECGF 
(Mr  20,000)  based  upon  protein  determinations  provided 
from amino acid compositions. 
Acidic FGF and EDGF-II React with Antibodies 
Against ECGF 
Monoclonal antibodies against ECGF have proven valuable 
as  reagents  to  assess  the  immunological  character  of the 
endothelial cell growth-promoting activity present in crude 
preparations of bovine brain (20).  Subsequently, these anti- 
bodies have also been used to inhibit the biological activity of 
purified ECGF, an observation consistent with the ability of 
the antibodies to prevent [12SI]ECGF  receptor occupancy (22). 
The data in Fig. 2A demonstrate that the murine monoclonal 
anti-ECGF antibody,  HI5,  binds  ECGF,  acidic  FGF,  and 
EDGF-II  in  a  concentration-dependent manner.  Further- 
more, it was possible to demonstrate that the polypeptides are 
recognized by two distinct anti-ECGF monoclonal antibodies, 
HI5 and H9, in a manner dependent upon the concentration 
of the antibody. These data suggest that ECGF, acidic FGF, 
and EDGF-II share common immunological epitopes which 
are recognized by two different monoclonal antibodies both 
of which inhibit ECGF-induced endothelial cell proliferation 
(20,  22). Denaturation of the polypeptide preparations may 
explain the relatively small differences in cross-reactivity be- 
tween EDGF-II, ECGF, and acidic FGF. 
The Mitogenic Activity of ECGF, Acidic FGF, and 
EDGF-II Is Potentiated by Heparin 
It  is established that  the  mitogenic  activity  of crude  (25) 
and purified preparations of ECGF  (20, 22) is potentiated by 
the  glycosaminoglycan,  heparin.  Since  ECGF,  acidic  FGF, 
and EDGF-II  share common  receptor binding and immuno- 
logical characteristics, we examined  the ability of heparin to 
potentiate the biological activity of EDGF-II and acidic FGF. 
As demonstrated  in Fig. 3, ECGF,  acidic FGF, and EDGF-II 
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FIGURE  1  Competition of binding of [12Sl]ECGF to BAEC by ECGF, 
EDGF-II,  and  acidic  I-GF.  BAEC  grown  to  confluence  in  DME 
supplemented with  10% fetal bovine serum. The cells were incu- 
bated  at 4°C  for  1  h  with  10  -9  M  [12Sl]ECGF  in  the absence  or 
presence of increasing concentrations of unlabeled ECGF (O), acidic 
FGF  (A),  EDGF-II  (FI), cationic  FGF  (~7), or  EGF  (O).  Results  are 
reported  as  the  percent  [12Sl]ECGF  bound  as  a  function  of  the 
concentration of unlabeled competing ligand. 1.0 
E  t- 
O 
tt~ 
~" 0.5 
<( 
I  I  I 
A 
0  1  I  I 
1  10  100 
GROWTH  FACTOR  CONCENTRATION 
(ng/ml) 
1.0 
0.5 
1  I  l 
I  I  1 
1  10  100 
ANTIBODY CONCENTRATION 
(M  x  10  e) 
FIGURE 2  Reactivity of anti-ECGF antibodies with ECGF, EDGF-II, and acidic FGF. (A) Rabbit polyclonal anti-ECGF antibodies 
(50/zg/ml) were adsorbed to solid-phase polyvinylchloride  plates. After countercoating, increasing concentrations of either ECGF 
(O), acidic FGF (A), or EDGF-II (I-I) were incubated at 37"C for 2 h. The plates were washed, further incubated at 37°C for 2 h 
with 10  -6 M HI5 murine monoclonal IgG anti-ECGF, washed, and the binding of HI5 IgG was determined spectrophotometrically 
after incubation with rabbit anti-mouse IgG antiserum coupled to perioxidase. The results are reported as antibodies at 450 nm 
(orthophenylenediamine  conversion.)  (B) Same protocol as in A except that the ligand concentration remained constant at 100 
ng/ml of either ECGF (O), acidic FGF (A), or EDGF-II (D). Increasing concentrations of either HI5 murine monoclonal anti-ECGF 
(open symbols) or H9 murine monoclonal anti-ECGF (closed  symbols) were added at 370C for 2 h.  Results are reported as 
orthophenylenediamine  conversion (antibodies at 450 nm) as a function of the concentration of the monoclonal anti-ECGF 
antibody. 
are indeed potent endothelial cell mitogens. In addition, the 
biological  activities of EDGF-II, acidic FGF, and ECGF are 
potentiated by heparin. The effect of heparin on the potentia- 
tion of biological  activity is very similar among these poly- 
peptides.  The half-maximal mitogenic response for EDGF-II, 
ECGF, and acidic FGF is between  2  and 4  ng/ml in  the 
presence of heparin. 
DISCUSSION 
A number of laboratories have recently purified anionic poly- 
peptides from a variety of bovine tissues. These polypeptides 
share  a  common  feature  since  they are  potent  biological 
mitogens for endothelial cells in vitro (1-3, 5, 7,  15,  17,  19, 
24). They also share common chemical and physical charac- 
teristics including similar isoelectric points (pI's) and molec- 
ular weights and the ability to avidly bind immobilized hep- 
arin (5, 6,  15, 20). These polypeptides have been designated 
ECGF (18), acidic FGF (9, 24), EDGF-II (1-3), RDGF (6), 
a-HGF (17), and acidic HDGF (15). We report that three of 
these endothelial cell mitogens share considerable biochemical 
homology which includes (a) heparin affinity, (b) cross-reac- 
tivity to polyclonal ECGF antisera and monoclonal ECGF 
antibodies, (c) competition with ECGF for binding to a high 
affinity endothelial cell--derived receptor (22), and (d) potent 
biological activity as endothelial cell mitogens which is poten- 
tiated  by  heparin  (22).  Furthermore,  antibodies  prepared 
against ECGF inhibit the mitogenic activity of acidic FGF 
and EDGF-II (data not presented);  this observation is con- 
sistent with the ability of anti-ECGF antibodies to prevent 
receptor occupancy by ECGF (22). These biological attributes, 
together with biochemical similarities among ECGF, acidic 
FGF,  and  EDGF-II  (1,  19,  24),  strongly argue that these 
endothelial cell mitogens are either identical or belong to the 
same family of polypeptide growth factors. Furthermore, our 
data suggest that this new polypeptide growth factor family, 
as defined by biological, immunological (20), and radiorecep- 
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FIGURE 3  Potentiation  of the mitogenic activity of ECGF, EDGF-II, 
and acidic FGF by heparin.  The mitogenic response of BAEC to 
ECGF (O), acidic FGF (A), and EDGF-II (l'q) was determined in the 
absence (open symbols) and presence (closed symbols) of heparin 
(50/zg/ml) as described previously (20, 22). The results are reported 
as the  percent incorporation of  [3H]dThd  into  DNA versus the 
protein concentration of the various polypeptide ligands. 
tor (22) criteria, is unique and distinct from other traditional 
growth factor families such as nerve growth, EGF, bovine 
basic FGF, insulin-like growth factors I and II, and platelet- 
derived growth factor (13). 
Although we have not established  a relationship between 
RDGF (6), c~-HGF (17), and acidic HDGF (15) at the im- 
munological and receptor level, comparative biochemical and 
biological  information does exist  which suggest that acidic 
HDGF,  c~-HGF, and RDGF are  indeed homologous with 
acidic FGF, EDGF-I1, and ECGF (6,  15,  17). These homol- 
ogies are substantiated by common molecular weights, acidic 
pI's, avid affinity for immobilized heparin (6, 15, 17), and, in 
the case of a-HGF, similar amino acid compositions (l 7, 24) 
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Although these similarities are tentative and will require ex- 
perimental verification at either the protein or gene level, we 
propose  that  c~-HGF,  acidic  HDGF,  and  RDGF  will  ulti- 
mately belong to  the  family  of endothelial  cell  polypeptide 
mitogens which  presently  includes  ECGF,  acidic  FGF,  and 
EDGF-II. 
Historically,  interest in polypeptide mitogens for endothe- 
lial cells has been stimulated by the ubiquitous nature of the 
endothelium and the potential role of the endothelial cell in 
maintenance of homeostasis (7, 8,  12, 21). Clearly, polypep- 
tides  capable  of inducing  endothelial  cell  proliferation  may 
have a  significant  impact  on our understanding  of the bio- 
chemical  responsibilities  of the endothelium  during the de- 
velopment of the vascular tree, wound healing, tumor devel- 
opment,  and atherogenesis (21).  Biochemical  interest in the 
structure  of these endothelial  cell polypeptide  mitogens  has 
been driven by the need to elucidate the contribution of the 
endothelial cell to normal and pathophysiological neovascu- 
larization (7, 8,  12, 21). This study demonstrates that ECGF, 
EDGF-II,  and  acidic  FGF  belong  to  the  same  family  of 
endothelial cell polypeptide mitogens. 
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